AMRXのチャート
AMRXの企業情報
| symbol | AMRx |
|---|---|
| 会社名 | Amneal Pharmaceuticals Inc （AMRX アムニ―ル・ファ―マシュ―ティカルズ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アムニール・ファーマシューティカルズ(Amneal Pharmaceuticals Inc.)は専門医薬会社である。同社は、ブランド製品の開発・マーケティング、及び生物学的同等医薬品（ジェネリック医薬品）の開発・製造・販売に従事する。同社は2つの事業セグメントを運営する。Impaxジェネリックスは、ブランド名の医薬品の医薬品および治療剤と同等の薬品名で販売されている同社のジェネリック医薬品の開発・製造・販売・流通に従事する。Impax専門製薬事業は、パーキンソン病（PD）、脳炎後パーキンソニズムおよびパーキンソニズムの治療用カルビドパ - レボドパの持続放出経口カプセル製剤であるRytary等のブランド医薬品、並びに片頭痛の治療に適応されたゾミグ（ゾルミトリプタン）製品を含む複数のブランド製品の宣伝・販売・流通に従事する。 インパックス・ラボラトリ―ズは、米国の製薬会社。ジェネリック医薬品の開発、製造、販売、流通を中心に行うほか、片頭痛、多発性硬化症、パ―キンソン病、帯状疱疹後の神経痛など中枢神経系障害の治療のため自社ブランド医薬品の開発を手掛ける。主要製品は「Adderall XR」、「Trilipix」、「RYTARY」など。 Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States. |
| 本社所在地 | 908 947-3120 |
| 代表者氏名 | Paul M. Bisaro |
| 代表者役職名 | Executive Chairman of the Board |
| 電話番号 | +1 908-409-6700 |
| 設立年月日 | 34060 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 6000人 |
| url | www.amneal.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 373.66200 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 4233.95800 |
| 売上高 | 売上高（百万ドル） 1662.99100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6711.96000 |
| 当期純利益 | 当期純利益（百万ドル） -21.12000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Amneal Pharmaceuticals Inc revenues increased from $775.8M to $1.66B. Net loss applicable to common stockholders excluding extraordinary items decreased 96% to $21.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects In-process research and development impa decrease of 80% to $39.3M (expense). |
AMRXのテクニカル分析
AMRXのニュース
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2023 Earnings Call Transcript 2023/05/05 17:25:23 Seeking Alpha
Amneal Pharmaceuticals, Inc. (NYSE:NYSE:AMRX) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ETCompany ParticipantsTony DiMeo - Head-Investor RelationsChirag Patel - President &…
Amneal Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation 2023/05/05 15:43:41 Seeking Alpha
The following slide deck was published by Amneal Pharmaceuticals, Inc.
Amneal Pharma Q1 Exceeds Consensus View On Strength In Complex Generics Portfolio 2023/05/05 13:51:42 Benzinga
Amneal Pharmaceuticals Inc (NYSE: AMRX ) reported first-quarter FY23 revenue of $557.54 million, an increase of 12% year over year, beating the consensus of $537.31 million . Adjusted EPS was $0.12, beating the consensus of $0.10, and was flat Y/Y. The increase was driven by growth across all … Full story available on Benzinga.com
Recap: Amneal Pharmaceuticals Q1 Earnings 2023/05/05 11:02:25 Benzinga
Amneal Pharmaceuticals (NYSE: AMRX ) reported its Q1 earnings results on Friday, May 5, 2023 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Amneal Pharmaceuticals beat estimated earnings by 20.0%, reporting an EPS of $0.12 versus an estimate of $0.1. Revenue was up $59.91 million from the same period last … Full story available on Benzinga.com
Amneal: Q1 Earnings Snapshot 2023/05/05 10:09:29 WTOP
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $6.9 million…
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023 2023/01/31 13:00:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023. The financial results and live webcast will be accessible through the Investor Relations section of the Company''s website at https://invest
Intercept Surges To Four-Month High After Staving Off Amneal''s Generic For 11 Years 2023/01/25 18:15:30 Investor''s Business Daily
Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.
ICPT stock gains after patent settlement with Amneal (NASDAQ:ICPT) 2023/01/25 17:44:58 Seeking Alpha
Intercept Pharma (ICPT) shares gained Wednesday after a deal with generic drugmaker Amneal Pharma (AMRX) to settle a patent dispute over liver drug Ocaliva. Read the full story here.
Amneal: Downside Risk Persists (NYSE:AMRX) 2023/01/23 17:29:39 Seeking Alpha
Inability to efficiently market new drugs might put significant pressure on Amneal''s margins. Read more to see AMRX stock''s growth opportunities and risks.
Amneal Pharmaceuticals Inc. (NYSE: AMRX): The Metrics That Matter Right Now 2023/01/14 17:00:00 Stocks Register
Amneal Pharmaceuticals Inc. (NYSE:AMRX) price on Friday, January 13, fall -0.45% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.22. A look at the stock’s price movement, the close in the last trading session was $2.23, moving within a range at $2.18 and $2.265. The beta value … Amneal Pharmaceuticals Inc. (NYSE: AMRX): The Metrics That Matter Right Now Read More »
Amneal Pharma begins commercial operations in India 2022/10/11 04:53:58 Express Pharma
Appoints Shyamakant Giri as Managing Director and President for India Business and Emerging Markets The post Amneal Pharma begins commercial operations in India appeared first on Express Pharma .
New Jersey-based Amneal Pharma starts mfg operations for Indian market 2022/10/10 10:42:00 Business Standard
The firm already has manufacturing units in four Indian cities, all of which are focused on the export market
Amneal Pharma starts commercial operations in India 2022/10/10 09:41:34 The Hindu BusinessLine
Appoints Shyamakant Giri, Managing Director and President, India Business and Emerging Markets
Amneal Launches First Biosimilar with ALYMSYS (bevacizumab-maly) in the United States 2022/10/03 20:05:00 Wallstreet:Online
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin. ALYMSYS is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization
Do investors need to be concerned about Amneal Pharmaceuticals Inc. (AMRX)? 2022/09/21 13:48:00 US Post News
Amneal Pharmaceuticals Inc. (NYSE:AMRX) closed Tuesday at $2.29 per share, up from $2.27 a day earlier. While Amneal Pharmaceuticals Inc. has overperformed by 0.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AMRX fell by -53.74%, with highs and lows ranging from $5.99 to $2.15, whereas […]